Efficacy and safety of tedizolid in a patient with linezolid-induced neutropenia: A case report

Int J Clin Pharmacol Ther. 2021 Jun 30. doi: 10.5414/CP204007. Online ahead of print.

ABSTRACT

Linezolid is used to treat prosthetic joint infection after total hip arthroplasty. Here, we present a case of linezolid-induced severe neutropenia, which improved after switching to tedizolid. Grade 3 neutropenia developed 5 days after linezolid injection (1,200 mg/day) and 33 days after oral administration of the same dose. However, during the 70 days of treatment with tedizolid, grade 3 neutropenia did not occur, and C-reactive protein levels remained in the normal range. No grade ≥ 1 thrombocytopenia or bleeding event occurred during the course of tedizolid treatment. Tedizolid may be an alternative drug for patients who develop linezolid-induced neutropenia.

PMID:34190685 | DOI:10.5414/CP204007